98 completed. 98 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 98 | Completed 98 |
| Phase 2 | 6 | Completed 6 |
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase â…¢ Clinical Trial of sIPV Vaccine Sabin Strain Inactivated Poliovirus Vaccine - Poliomyelitis, Polio | Phase 3 | Completed | Sinovac Biotech Co., Ltd | 1442 | 2023-05-22 | 2025-12-18 |
| A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants sIPV+bOPV, wIPV+bOPV - Poliomyelitis | Phase 3 | Completed | Beijing Minhai Biotechnology Co., Ltd | 300 | 2023-03-08 | 2024-12-30 |
| Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants Eupolio - Poliomyelitis, Vaccine Reaction | Phase 3 | Completed | LG Chem | 2001 | 2023-01-10 | 2025-04-06 |
| Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C - Poliomyelitis | Phase 3 | Completed | Serum Institute of India Pvt. Ltd. | 1072 | 2022-01-09 | 2023-10-23 |
| Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants nOPV2 - Poliomyelitis | Phase 3 | Completed | Fidec Corporation | 905 | 2021-12-16 | 2024-08-23 |
| Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants Experimental vaccine, IPV control vaccine, single-person sIPV control vaccine - Poliomyelitis | Phase 3 | Completed | Sinovac Biotech Co., Ltd | 1572 | 2020-11-05 | 2024-04-15 |
| Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age, Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age, Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age - Poliomyelitis | Phase 3 | Completed | Sinovac Biotech Co., Ltd | 1300 | 2020-05-11 | 2021-08-18 |
| An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Ravulizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 58 | 2019-12-09 | 2025-10-14 |
| Confirmatory Study of BK1310 in Healthy Infants DPT-IPV-Hib, Hib vaccine, DPT-IPV - Tetanus, Diphtheria | Phase 3 | Completed | Tanabe Pharma Corporation | 267 | 2019-04-01 | 2026-01-06 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants sIPV-sIPV-bOPV vaccination schedule, wIPV-wIPV-bOPV vaccination schedule - Poliomyelitis | Phase 3 | Completed | Sinovac Biotech Co., Ltd | 240 | 2018-06-12 | 2019-01-31 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants sIPV-bOPV-bOPV vaccination schedule, wIPV-bOPV-bOPV vaccination schedule - Poliomyelitis | Phase 3 | Completed | Sinovac Biotech Co., Ltd | 240 | 2018-06-06 | 2019-01-30 |
| Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months IPV-Al SSI - Poliomyelitis | Phase 3 | Completed | Statens Serum Institut | 666 | 2018-05-15 | 2018-11-14 |
| A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV IPV, f-IPV - Poliomyelitis | Phase 3 | Completed | Fidec Corporation | 773 | 2017-10-23 | 2023-07-21 |
| Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) sIPV, wIPV - Poliomyelitis | Phase 3 | Completed | Beijing Minhai Biotechnology Co., Ltd | 1200 | 2017-08-21 | 2025-12-22 |
| An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants Investigational sIPV, Control IPV - Poliomyelitis | Phase 3 | Completed | Sinovac Biotech Co., Ltd | 1200 | 2017-08-08 | 2019-01-25 |
| A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants Inactivated Poliomyelitis Vaccine (Sabin strain), Inactivated Poliomyelitis Vaccine (Salk strain) - Poliomyelitis | Phase 2 / Phase 3 | Completed | LG Chem | 1417 | 2017-05-31 | 2019-08-29 |
| Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months IPV-Al SSI, IPV SSI - Poliomyelitis | Phase 3 | Completed | Statens Serum Institut | 1002 | 2017-02-06 | 2018-11-14 |
| Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age IPV-Al SSI, IPV SSI - Poliomyelitis | Phase 3 | Completed | Statens Serum Institut | 800 | 2017-01-19 | 2018-11-14 |
| DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 53 | 2016-07-14 | 2022-04-05 |
Showing 20 of 98. Sign in to see all of them.
Poliomyelitis (89) · Diphtheria (60) · Tetanus (56) · Whooping Cough (45) · Haemophilus Infections (37) · Hepatitis B (34) · Bacterial Infections (4) · Paraparesis, Tropical Spastic (4) · Virus Diseases (4) · Postpoliomyelitis Syndrome (3) · Demyelinating Diseases (2) · Measles (2) · Meningitis, Bacterial (2) · Myelitis, Transverse (2) · Neuromyelitis Optica (2)
Central Nervous System Diseases (98) · Central Nervous System Infections (98) · Infections (98) · Nervous System Diseases (98) · Neuroinflammatory Diseases (98) · Spinal Cord Diseases (98) · RNA Virus Infections (96) · Enterovirus Infections (92) · Neuromuscular Diseases (92) · Picornaviridae Infections (92) · Virus Diseases (92) · Actinomycetales Infections (60) · Bacterial Infections and Mycoses (60) · Corynebacterium Infections (60)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (15) · DTaP-IPV-HB-PRP-T vaccine (9) · Diphtheria-Tetanus-acellular Pertussis Vaccines (8) · Heptavalent Pneumococcal Conjugate Vaccine (7) · Pentavac (7) · Poliovirus Vaccine, Inactivated (7) · Tetanus Toxoid (7) · pentacel (6) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (5) · 13-valent pneumococcal vaccine (4) · Hiberix (4) · Hepatitis B Vaccines (3) · HibTITER protein, Haemophilus influenzae (3) · RIX4414 vaccine (3) · RotaTeq (3)
Sanofi Pasteur, a Sanofi Company (27) · GlaxoSmithKline (19) · Sanofi (9) · Sinovac Biotech Co., Ltd (6) · Merck Sharp & Dohme LLC (5) · Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · LG Chem (3) · Statens Serum Institut (3) · Alexion Pharmaceuticals, Inc. (2) · Beijing Minhai Biotechnology Co., Ltd (2) · Centers for Disease Control and Prevention (2) · Fidec Corporation (2) · Imperial College London (2) · MCM Vaccines B.V. (2) · Azienda Ospedaliera Universitaria Integrata Verona (1)
China (18) · Germany (8) · South Korea (8) · United States (7) · France (5) · Japan (5) · Thailand (5) · United Kingdom (5) · Bangladesh (4) · Colombia (4) · India (4) · Italy (4) · Spain (4) · Costa Rica (3) · Mexico (3)
Ingrid Kromann (3) · Yuemei Hu (3) · Abhijeet Anand, MBBS, MPH (2) · Anne Fiquet, MD (1) · Changgui Li, PHD (1) · Dagmar Dilloo, MD, PhD (1) · Davi Costa, MD (1) · Dirk Fischer, Prof. (1) · Edgar M Carvalho, MD, PhD (1)
PMID 26873055, PMID 32273184, PMID 16984654, PMID 17090650, PMID 19117896, PMID 19952980, PMID 21219984, PMID 21289531, PMID 21334243, PMID 21441781, PMID 21807056, PMID 22001281, PMID 22157567, PMID 22273029, PMID 22349525, PMID 22475857, PMID 22531237, PMID 22691430, PMID 22720101, PMID 23966556, PMID 25765966, PMID 27288217, PMID 27510380, PMID 27846055, PMID 27846058, PMID 27879555, PMID 28274276, PMID 29576304, PMID 30958543, PMID 31703934, PMID 32307307, PMID 32676980, PMID 33284114, PMID 33351072, PMID 33676197, PMID 34498507, PMID 35044877, PMID 37745024, PMID 38109921, PMID 38356884, PMID 38582691, PMID 40505670, PMID 41782198, PMID 42441931, PMID 42659917
2018 (1), 2019 (1)